AbbVie to Present 60 Dermatology Abstracts at 2026 EADV Congress in Vienna

AbbVie (ABBV) said it will present 60 abstracts, including three late-breaking presentations, across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology Congress in Vienna, Austria, on September 30, 2026. The data cover immune-mediated skin diseases including alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and psoriatic arthritis. Presentations include 52-week Phase 3 results for upadacitinib in severe alopecia areata and new efficacy and safety analyses in non-segmental vitiligo and atopic dermatitis. AbbVie will also report data on investigational therapies zumilokibart, an extended half-life anti-IL-13 antibody, in moderate-to-severe atopic dermatitis, and lutikizumab, which targets IL-1a and IL-1ß, in hidradenitis suppurativa. Additional presentations feature risankizumab data in psoriasis, including pediatric patients, and five-year radiographic progression data in psoriatic arthritis. ABBV traded at $263.27, down 0.01%.